123.0K XNAS Volume
XNAS 21 Mar, 2025 12:34 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dominic Smethurst | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.78 per share. | 06 Mar 2025 | 6,393 | 70,807 (0%) | 0% | 6.8 | 43,330 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 14 Feb 2025 | 2,792 | 73,313 (0%) | 0% | 8.8 | 24,446 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 14 Feb 2025 | 7,134 | 138,187 (0%) | 0% | 8.8 | 62,465 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 27,500 | 76,105 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 92,500 | 92,500 | - | - | Stock options (right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 68,100 | 145,321 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 228,800 | 228,800 | - | - | Stock options (right to buy) | |
| Dominic Smethurst | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 91,200 | 91,200 | - | - | Stock options (right to buy) | |
| Dominic Smethurst | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 27,200 | 77,200 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,566 | 5,566 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,566 | 5,566 | - | - | Stock options (right to buy) | |
| Alan F. Holmer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,667 | 0 | - | - | Options to purchase common stock | |
| Alan F. Holmer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,667 | 5,829 (0%) | 0% | 30 | 50,010 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,567 | 50,172 (0%) | 0% | 30 | 47,010 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,958 | 0 | - | - | Options to purchase common stock | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 6,730 | 11,217 | - | - | Options to purchase common stock | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 7,788 | 23,367 | - | - | Options to purchase common stock | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,567 | 1,958 | - | - | Options to purchase common stock | |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.12 per share. | 14 Jun 2024 | 1,958 | 48,605 (0%) | 0% | 42.1 | 82,479 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,958 | 50,563 (0%) | 0% | 30 | 58,740 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.77 per share. | 14 Jun 2024 | 6,730 | 48,605 (0%) | 0% | 46.8 | 314,789 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 6,730 | 55,335 (0%) | 0% | 14.1 | 94,893 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 7,788 | 48,605 (0%) | 0% | 49.9 | 388,417 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 7,788 | 56,393 (0%) | 0% | 4.3 | 33,177 | Common Stock, par value $0.0001 per share |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 1,567 | 48,605 (0%) | 0% | 49.9 | 78,152 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 1,770 | 84,400 (0%) | 0% | 42.2 | 74,759 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 16,830 | 101,230 (0%) | 0% | 14.1 | 237,303 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 14 Jun 2024 | 16,830 | 84,400 (0%) | 0% | 50.2 | 844,297 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 12,487 | 96,887 (0%) | 0% | 4.3 | 53,195 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 14 Jun 2024 | 12,487 | 84,400 (0%) | 0% | 50.2 | 626,425 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 9,333 | 93,733 (0%) | 0% | 30 | 279,990 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 14 Jun 2024 | 9,333 | 84,400 (0%) | 0% | 46.0 | 429,507 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 1,770 | 86,170 (0%) | 0% | 4.3 | 7,540 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 14 Jun 2024 | 1,770 | 84,400 (0%) | 0% | 46.0 | 81,456 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 11,667 | 96,067 (0%) | 0% | 30 | 350,010 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 11,667 | 84,400 (0%) | 0% | 42.2 | 492,779 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 1,770 | 86,170 (0%) | 0% | 14.1 | 24,957 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 2,322 | 86,722 (0%) | 0% | 4.3 | 9,892 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 2,322 | 84,400 (0%) | 0% | 42.2 | 98,074 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 7,179 | 77,221 (0%) | 0% | 42.2 | 303,219 | Common Stock, par value $0.0001 per share |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 16,830 | 32,827 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 12,487 | 53,831 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 9,333 | 11,667 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,770 | 52,061 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 11,667 | 0 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,770 | 31,057 | - | - | Options to purchase common stock | |
| Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 2,322 | 49,739 | - | - | Options to purchase common stock | |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 4,350 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 4,162 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,816 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Anne Altmeyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Anne Altmeyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 1,787 | 0 | - | - | Employee Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 10 Apr 2024 | 1,787 | 48,605 (0%) | 0% | 30 | 53,610 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 73,947 | 84,400 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Moran F. Sean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 40,176 | 46,818 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 73,947 | 73,947 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 40,176 | 40,176 | - | - | Stock Option (right to buy) | |
| Alan F. Holmer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.97 per share. | 26 Jan 2024 | 629 | 1,379 (0%) | 0% | 5.0 | 3,126 | Common Stock |
| Cohen Yuval | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 7,179 | 0 | - | - | Options to purchase common stock | |
| Alan F. Holmer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 629 | 0 | - | - | Options to purchase common stock | |
| Cohen Yuval | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.97 per share. | 26 Jan 2024 | 7,179 | 7,179 (0%) | 0% | 5.0 | 35,680 | Common Stock |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Rachelle Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Anne Altmeyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | |
| Yong Ben | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 5,307 | 5,307 | - | - | Stock Option(right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 934,645 | 934,645 | - | - | Stock Option (right to buy) | |
| Craig Stuart Millian | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 934,645 | 934,645 | - | - | Stock Option (right to buy) | |
| Rachael Louise Brake | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,400,000 | 1,400,000 | - | - | Stock Option (right to buy) | |
| Anne Altmeyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2022 | 159,200 | 159,200 | - | - | Stock Option(right to buy) | |
| Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.26 per share. | 10 Aug 2022 | 20,000 | 199,272 (0%) | 0% | 0.3 | 5,198 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.26 per share. | 10 Aug 2022 | 3,800 | 98,230 (0%) | 0% | 0.3 | 1,003 | Common Stock |
| Craig Stuart Millian | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.25 per share. | 10 Aug 2022 | 5,000 | 27,000 (0%) | 0% | 0.3 | 1,273 | Common Stock |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | |
| Rachelle Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | |
| Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 16 May 2022 | 12,000 | 179,272 (0%) | 0% | 0.3 | 3,600 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.25 per share. | 16 May 2022 | 10,500 | 94,430 (0%) | 0% | 0.3 | 2,625 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 10 Mar 2022 | 15,000 | 167,272 (0%) | 0% | 0.4 | 5,550 | Common Stock |
| Craig Stuart Millian | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 10 Mar 2022 | 10,000 | 22,000 (0%) | 0% | 0.4 | 3,700 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 09 Mar 2022 | 8,600 | 83,930 (0%) | 0% | 0.4 | 3,182 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 1,989,546 | 1,949,546 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 538,400 | 538,400 | - | - | Stock Option (right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 1,489,700 | 1,489,700 | - | - | Stock Option (right to buy) | |
| Craig Stuart Millian | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 402,900 | 402,900 | - | - | Stock Option (right to buy) | |
| Rachael Louise Brake | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 570,800 | 570,800 | - | - | Stock Option (right to buy) | |
| Rachael Louise Brake | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2021 | 500,000 | 500,000 | - | - | Stock Option(right to buy) | |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Rachelle Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Rachelle Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 956,500 | 956,500 | - | - | Stock Option (right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 956,500 | 956,500 | - | - | Stock Option (right to buy) | |
| Barbara White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Barbara White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Craig Stuart Millian | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Craig Stuart Millian | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. | 18 Dec 2020 | 53,610 | 403,220 (0%) | 0% | 1 | 53,610 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 87,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 53,610 | 53,610 | - | - | Stock Option (Right to Buy) | |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 18 Dec 2020 | 87,500 | 349,610 (0%) | 0% | 1.8 | 153,125 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.40 per share. | 18 Dec 2020 | 87,500 | 437,110 (0%) | 0% | 1.4 | 122,500 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 18 Dec 2020 | 53,610 | 349,610 (0%) | 0% | 1.4 | 75,054 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.17 per share. | 16 Dec 2020 | 36,923 | 386,533 (0%) | 0% | 0.2 | 6,118 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 36,923 | 36,923 | - | - | Stock Option (Right to Buy) | |
| Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 16 Dec 2020 | 36,923 | 349,610 (0%) | 0% | 1.3 | 48,628 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.21 per share. | 11 Nov 2020 | 4,240 | 75,330 (0%) | 0% | 1.2 | 5,126 | Common Stock |
| Avery W. Catlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| David P. Hochman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| Alan F. Holmer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| John K. Jenkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| Rachelle Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2020 | 40,500 | 40,500 | - | - | Stock Option(right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.49 per share. | 17 Mar 2020 | 4,300 | 71,090 (0%) | 0% | 3.5 | 15,007 | Common Stock |
| Barbara White | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 3.63 per share. | 17 Mar 2020 | 15,606 | 206,217 (0%) | 0% | 3.6 | 56,650 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 4.25 per share. | 17 Mar 2020 | 2,000 | 12,000 (0%) | 0% | 4.3 | 8,500 | Common Stock |
| Robert Paul Discordia | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 3.54 per share. | 17 Mar 2020 | 2,840 | 35,490 (0%) | 0% | 3.5 | 10,054 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 226,000 | 226,000 | - | - | Stock Option(right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 639,000 | 639,000 | - | - | Stock Option(right to buy) | |
| Barbara White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 226,000 | 226,000 | - | - | Stock Option(right to buy) | |
| Craig Stuart Millian | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 226,000 | 226,000 | - | - | Stock Option(right to buy) | |
| Robert Paul Discordia | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 226,000 | 226,000 | - | - | Stock Option(right to buy) | |
| Peter Salzmann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 66,600 | 66,600 | - | - | Stock Option(right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.26 per share. | 12 Nov 2019 | 1,430 | 66,790 (0%) | 0% | 4.3 | 6,092 | Common Stock |
| Barbara White | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.38 per share. | 12 Nov 2019 | 3,424 | 190,611 (0%) | 0% | 4.4 | 14,992 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 4.38 per share. | 11 Nov 2019 | 1,000 | 10,000 (0%) | 0% | 4.4 | 4,380 | Common Stock |
| Robert Paul Discordia | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 4.62 per share. | 11 Nov 2019 | 2,500 | 32,650 (0%) | 0% | 4.6 | 11,559 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 5.48 per share. | 15 Aug 2019 | 1,500 | 9,000 (0%) | 0% | 5.5 | 8,213 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.06 per share. | 12 Aug 2019 | 1,175 | 65,360 (0%) | 0% | 6.1 | 7,116 | Common Stock |
| Barbara White | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 6.10 per share. | 12 Aug 2019 | 1,639 | 187,187 (0%) | 0% | 6.1 | 9,998 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 12 Aug 2019 | 1,500 | 7,500 (0%) | 0% | 6 | 9,000 | Common Stock |
| Robert Paul Discordia | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 5.86 per share. | 12 Aug 2019 | 15,000 | 30,150 (0%) | 0% | 5.9 | 87,894 | Common Stock |
| Robert Paul Discordia | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2019 | 100,000 | 100,000 | - | - | Stock Option(right to buy) | |
| Avery W. Catlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| David P. Hochman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| Alan F. Holmer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| Paris Panayiotopoulos | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| John K. Jenkins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| Rachelle Jacques | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2019 | 33,300 | 33,300 | - | - | Stock Option(right to buy) | |
| Barbara White | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 7.20 per share. | 17 May 2019 | 1,389 | 185,548 (0%) | 0% | 7.2 | 10,001 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 7.12 per share. | 14 May 2019 | 100 | 349,610 (0%) | 0% | 7.1 | 712 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 7.23 per share. | 14 May 2019 | 1,000 | 6,000 (0%) | 0% | 7.2 | 7,227 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.99 per share. | 13 May 2019 | 995 | 64,185 (0%) | 0% | 7.0 | 6,955 | Common Stock |
| Rachelle Jacques | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2019 | 68,000 | 68,000 | - | - | Stock Option(right to buy) | |
| David P. Hochman | None | Purchase of securities on an exchange or from another person at price $ 6.98 per share. | 15 Mar 2019 | 2,000 | 7,000 (0%) | 0% | 7.0 | 13,958 | Common Stock |
| John K. Jenkins | None | Purchase of securities on an exchange or from another person at price $ 6.98 per share. | 15 Mar 2019 | 1,000 | 1,000 (0%) | 0% | 7.0 | 6,978 | Common Stock |
| Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.67 per share. | 14 Mar 2019 | 1,500 | 349,510 (0%) | 0% | 6.7 | 10,005 | Common Stock |
| Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.49 per share. | 14 Mar 2019 | 1,530 | 63,190 (0%) | 0% | 6.5 | 9,930 | Common Stock |
| Barbara White | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 6.47 per share. | 14 Mar 2019 | 4,638 | 184,159 (0%) | 0% | 6.5 | 29,994 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 6.85 per share. | 14 Mar 2019 | 5,000 | 5,000 (0%) | 0% | 6.9 | 34,259 | Common Stock |
| Craig Stuart Millian | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 180,000 | 180,000 | - | - | Stock Option(right to buy) | |
| Mark A. Tepper | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2019 | 195,000 | 195,000 | - | - | Stock Option(right to buy) | |
| Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2019 | 195,000 | 195,000 | - | - | Stock Option(right to buy) | |
| Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2019 | 565,000 | 565,000 | - | - | Stock Option(right to buy) | |
| Barbara White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2019 | 195,000 | 195,000 | - | - | Stock Option(right to buy) | |
| Mark A. Tepper | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2018 | 10,000 | 261,600 | - | - | Option to purchase common stock | |
| Mark A. Tepper | President and CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. | 14 Nov 2018 | 10,000 | 2,110,400 (3%) | 0% | 1 | 10,000 | Common Stock |